These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 29299769)

  • 21. The annual costs associated with human papillomavirus types 6, 11, 16, and 18 infections in Finland.
    Herse F; Reissell E
    Scand J Infect Dis; 2011 Mar; 43(3):209-15. PubMed ID: 21171829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age-based programs for vaccination against HPV.
    Elbasha EH; Dasbach EJ; Insinga RP; Haupt RM; Barr E
    Value Health; 2009; 12(5):697-707. PubMed ID: 19490561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of HPV vaccination in Belize.
    Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
    Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
    Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
    BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment patterns and associated costs for genital warts in Italy.
    Merito M; Largeron N; Cohet C; Timelli L; Boselli F; Matteelli A; Naldi L; Vittori G
    Curr Med Res Opin; 2008 Nov; 24(11):3175-83. PubMed ID: 18851777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
    Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Estimated Lifetime Medical Cost of Diseases Attributable to Human Papillomavirus Infections Acquired in 2018.
    Chesson HW; Laprise JF; Brisson M; Martin D; Ekwueme DU; Markowitz LE
    Sex Transm Dis; 2021 Apr; 48(4):278-284. PubMed ID: 33492104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Burden of Disease of Human Papillomavirus (HPV): Hospitalizations in the Marche and Veneto Regions. An observational study.
    Mennini FS; Fabiano G; Marcellusi A; Sciattella P; Saia M; Cocchio S; Baldo V
    Clin Drug Investig; 2018 Feb; 38(2):173-180. PubMed ID: 29081028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
    Aljunid S; Zafar A; Saperi S; Amrizal M
    Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reducing the health burden of HPV infection through vaccination.
    Soper D
    Infect Dis Obstet Gynecol; 2006; 2006 Suppl():83084. PubMed ID: 16967913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The costs of treating vaginal and vulval cancer in England (2009-2015).
    Stephens S; Chatterjee A; Coles V; Crawford R
    BMC Public Health; 2020 Apr; 20(1):453. PubMed ID: 32252711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia.
    Van Kriekinge G; Sohn WY; Aljunid SM; Soon R; Yong CM; Chen J; Lee IH
    Asian Pac J Cancer Prev; 2018 Apr; 19(4):933-940. PubMed ID: 29693347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates.
    Ong KJ; Checchi M; Burns L; Pavitt C; Postma MJ; Jit M
    Sex Transm Infect; 2019 Feb; 95(1):28-35. PubMed ID: 30674687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.
    Thomas TL
    Pediatr Nurs; 2008; 34(5):429-31. PubMed ID: 19051848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.
    Guerrero AM; Genuino AJ; Santillan M; Praditsitthikorn N; Chantarastapornchit V; Teerawattananon Y; Alejandria M; Toral JA
    BMC Public Health; 2015 Jul; 15():730. PubMed ID: 26223975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
    Sharma M; Sy S; Kim JJ
    BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic burden of HPV9-related diseases: a real-world cost analysis from Italy.
    Mennini FS; Fabiano G; Favato G; Sciattella P; Bonanni P; Pinto C; Marcellusi A
    Eur J Health Econ; 2019 Aug; 20(6):829-840. PubMed ID: 30900047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.